What SPC protection does the UK cover for ertugliflozin?
An SPC (Supplementary Protection Certificate) is a UK mechanism that can extend patent protection for certain medicines beyond the normal patent term, specifically to compensate for time taken up during clinical trials and regulatory review. The exact scope for ertugliflozin depends on the specific UK SPC entry (the basic patent and the authorised product it references) and the dates stated in that record.
To answer precisely, you need the UK SPC record number (or the basic patent number) for ertugliflozin in the UK, because different SPCs can exist for different formulations or combinations, and the protected period can vary.
How do I find the ertugliflozin SPC record in the UK?
The quickest path is to search the UK Intellectual Property Office (UKIPO) SPC registers (or the UKIPO “Search patents/UK SPC” interfaces) using one of these:
- “ertugliflozin”
- the brand name under which it was authorised (if you know it)
- the applicant/holder name
- the basic patent number (if known)
The record typically shows:
- the granted SPC number
- the related basic patent
- the marketing authorisation details it is tied to
- the start and end dates of the SPC protection
When does a UK ertugliflozin SPC expire?
UK SPC expiry is determined by the specific SPC decision record (including the “effective date” and the “expiry date” shown there). Because expiry can differ by SPC and by product/authorisation link, you should use the date fields from the relevant UKIPO SPC entry rather than relying on general SGLT2 timing.
If you share either:
- the UK SPC number, or
- the basic patent number you’re using,
I can help you interpret the expiry dates shown on the record.
Can the UK SPC cover ertugliflozin combinations or just the single active?
SPCs in the UK are tied to a particular authorised product (as linked to the marketing authorisation referenced in the SPC). That means:
- A UK SPC for ertugliflozin alone does not automatically extend to combination products unless the SPC record explicitly covers that authorised product/formulation.
- Separate SPCs may exist for different combinations if the legal texts and marketing authorisations are different.
Does the UK SPC affect generics and biosimilar entry?
For small-molecule drugs like ertugliflozin, UK SPC protection can block or delay:
- the launch of generic products containing the same active ingredient(s) covered by the SPC, and
- certain regulatory steps that lead to commercial supply,
during the SPC period, assuming the generic product falls within the SPC’s protected scope.
The practical effect is usually determined by the SPC’s exact claim scope (active ingredient/product linkage) and enforcement posture in the UK.
What if there’s a patent/SPC dispute in the UK?
UK SPC validity and scope can be challenged through UK legal proceedings. Outcomes can change the practical availability window for competing products even if the record shows an initial end date.
If you’re looking at an SPC for planning freedom-to-operate, it’s important to check whether there are:
- invalidity actions,
- scope disputes (e.g., whether a challenger product is covered),
- any interim or final court decisions.
What information do you need from the SPC office to answer your exact question?
If your goal is “ertugliflozin UK patent office SPC” as a specific factual lookup, the minimum details needed are:
- the UK SPC number or application/reference number, or
- the basic patent number, or
- the authorised product name and marketing authorisation reference.
Send any one of those and I’ll help you pinpoint what the UKIPO record says about coverage and the protection end date.